Clinical Outcomes of Cyclosporine Treatment for Noninfectious Uveitis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To assess the clinical outcomes of cyclosporine treatment for noninfectious uveitis Methods: A retrospective review of medical records was completed for 182 noninfectious uveitis patients who were treated with cyclosporine between January 2001 and August 2010. Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use. Results: Uveitic activity was controlled to a level of minimal inflammation in 89.0% and completely in 78.6% of patients by the median duration of 49 and 98 days, respectively. Prednisolone-sparing (dose ≤10 mg) control of inflammation equal to or less than the minimal activity was achieved in 75.3% of patients. VA was aggravated more than 0.2 logarithm of the minimum angle of resolution in 17.3% of eyes in spite of cyclosporine treatment for the mean follow-up of 698.4 days. Dose reduction and cessation of cyclosporine was required only in 3.3% and 9.3%, respectively, due to the intolerable toxicity, although 44.0% of patients experienced mild to moderate adverse effects. Conclusions: Cyclosporine combined with corticosteroids or other immunosuppressive drugs as needed is an effective treatment for noninfectious uveitis, thus minimizing the adverse effects of corticosteroids and other toxic drugs. However, careful monitoring for the toxicity of cyclosporine is needed, because a small group of patients cannot tolerate its toxicity.
Abstract
Purpose: To assess the clinical outcomes of cyclosporine treatment for noninfectious uveitis Methods: A retrospective review of medical records was completed for 182 noninfectious uveitis patients who were treated with cyclosporine between January 2001 and August 2010. Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use. Results: Uveitic activity was controlled to a level of minimal inflammation in 89.0% and completely in 78.6% of patients by the median duration of 49 and 98 days, respectively. Prednisolone-sparing (dose ≤10 mg) control of inflammation equal to or less than the minimal activity was achieved in 75.3% of patients. VA was aggravated more than 0.2 logarithm of the minimum angle of resolution in 17.3% of eyes in spite of cyclosporine treatment for the mean follow-up of 698.4 days. Dose reduction and cessation of cyclosporine was required only in 3.3% and 9.3%, respectively, due to the intolerable toxicity, although 44.0% of patients experienced mild to moderate adverse effects. Conclusions: Cyclosporine combined with corticosteroids or other immunosuppressive drugs as needed is an effective treatment for noninfectious uveitis, thus minimizing the adverse effects of corticosteroids and other toxic drugs. However, careful monitoring for the toxicity of cyclosporine is needed, because a small group of patients cannot tolerate its toxicity.
참고문헌 (27)
- Murphy KP, "Janeway’s immunobiology. 7th ed", pp.659~660 (2008), Garland Science
- Nussenblatt RB, "Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents", Am J Ophthalmol, 96, pp.275~282 (1983)
- Calne RY, "Cyclosporin A in patients receiving renal allografts from cadaver donors", Lancet, 2, pp.1323~1327 (1978)
- Nussenblatt RB, "Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen", Am J Ophthalmol, 94, pp.147~158 (1982)
- Nussenblatt RB, "Cyclosporine therapy for uveitis: long-term followup", J Ocul Pharmacol, 1, pp.369~382 (1985)
- Binder AI, "Cyclosporin A in the treatment of severe Behçet’s uveitis", Br J Rheumatol, 26, pp.285~291 (1987)
- BenEzra D, "Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome", Transplant Proc, 20(3), pp.136~143 (1988)
- Le Hoang P, "Cyclosporine in the treatment of birdshot retinochoroidopathy", Transplant Proc, 20(3), pp.128~130 (1988)
- Masuda K, "Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease", Lancet, 1, pp.1093~1096 (1989)
- De Vries J, "Cyclosporin in the treatment of severe chronic idiopathic uveitis", Br J Ophthalmol, 74, pp.344~349 (1990)
- Secchi AG, "Cyclosporine-A in the treatment of serpiginous choroiditis", Int Ophthalmol, 14, pp.395~399 (1990)
- Nussenblatt RB, "Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis", Am J Ophthalmol, 112, pp.138~146 (1991)
- Ozyazgan Y, "Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial", Br J Ophthalmol, 76, pp.241~243 (1992)
- Vitale AT, "Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy", Ophthalmology, 101, pp.822~831 (1994)
- Araujo AA, "Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome", Br J Ophthalmol, 84, pp.979~982 (2000)
- Michel SS, "Multifocal choroiditis and panuveitis: immunomodulatory therapy", Ophthalmology, 109, pp.378~383 (2002)
- Ozdal PC, "Long-term therapy with low dose cyclosporin A in ocular Behcet’s disease", Doc Ophthalmol, 105, pp.301~312 (2002)
- Becker MD, "Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression", Ocul Immunol Inflamm, 13, pp.289~293 (2005)
- Kiss S, "Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy", Ophthalmology, 112, pp.1066~1071 (2005)
- Kacmaz RO, "Cyclosporine for ocular inflammatory diseases", Ophthalmology, 117, pp.576~584 (2010)
- Mathews D, "Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance", Indian J Ophthalmol, 58, pp.55~58 (2010)
- Kim HB, "Results of cyclotporin A therapy in Behcet’s disease", J Korean Ophthalmol Soc, 31, pp.469~475 (1990)
- Lee ET, "The effect of cyclosporin therapy on endogenous uveitis", J Korean Ophthalmol Soc, 38, pp.601~607 (1997)
- Jabs DA, "Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel", Am J Ophthalmol, 130, pp.492~513 (2000)
- Jabs DA, "Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop", Am J Ophthalmol, 140, pp.509~516 (2005)
- Tappeiner C, "Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis", Eye (Lond), 23, pp.1192~1198 (2009)
- Isnard Bagnis C, "Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study", J Am Soc Nephrol, 13, pp.2962~2968 (2002)